SLSSELLAS Life Sciences Group, Inc.
$11.66+615% 1Y
$11.66
$1.3952 weeks$15.47
SLS as reported
SELLAS Life Sciences Group, Inc. reported $422K of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed.
$422K
Revenue, trailing twelve months · to Q1 2024 · every figure below is as filed, with no scoring applied
- Net income
- −$32M
Net income · +24% year on year · trailing twelve months to Q2 2026
- EPS
- −$0.21
EPS · −34% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $422K | n/a | Q1 2024 · 9 quarters behind |
| Net income | −$32M | +24% | Q2 2026 |
| EPS | −$0.21 | −34% | Q2 2026 |
| Gross margin | 100% | n/a | Q1 2024 · 9 quarters behind |
| Operating margin | −11616% | n/a | Q1 2024 · 9 quarters behind |
| Net margin | −11515% | n/a | Q1 2024 · 9 quarters behind |
| ROE | −36% | n/a | Q2 2026 |
| ROA | −33% | n/a | Q2 2026 |
| ROIC | −72% | n/a | Q4 2017 · 34 quarters behind |
| Free cash flow | −$12M | n/a | Q4 2016 · 38 quarters behind |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
SELLAS Life Sciences Group, Inc. (SLS) · Revenue and profitRevenue and profitSELLAS Life Sciences Group, Inc. (SLS)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
On our screens:Most shorted stocks